Wall Street brokerages expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to announce earnings of ($0.56) per share for the current quarter, according to Zacks. Five analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.54). ACADIA Pharmaceuticals reported earnings of ($0.55) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1.8%. The firm is expected to report its next earnings report on Tuesday, February 26th.
On average, analysts expect that ACADIA Pharmaceuticals will report full-year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.03) to ($1.97). For the next financial year, analysts expect that the company will post earnings of ($1.77) per share, with EPS estimates ranging from ($1.92) to ($1.55). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.08. ACADIA Pharmaceuticals had a negative return on equity of 88.18% and a negative net margin of 119.62%. The firm had revenue of $58.31 million during the quarter, compared to analyst estimates of $56.31 million. During the same period last year, the company earned ($0.53) earnings per share. The business’s revenue for the quarter was up 63.9% on a year-over-year basis.
A number of equities analysts have recently commented on the company. BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 23rd. Cantor Fitzgerald raised their price target on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 1st. Leerink Swann assumed coverage on ACADIA Pharmaceuticals in a report on Monday, November 12th. They issued a “market perform” rating and a $21.00 price target for the company. Zacks Investment Research raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 29th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 1st. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $31.80.
In other ACADIA Pharmaceuticals news, Director Bros. Advisors Lp Baker acquired 11,764,705 shares of the company’s stock in a transaction that occurred on Friday, November 30th. The stock was bought at an average price of $17.00 per share, with a total value of $199,999,985.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 23.28% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in ACADIA Pharmaceuticals by 1.8% during the third quarter. Vanguard Group Inc. now owns 8,829,618 shares of the biopharmaceutical company’s stock valued at $183,303,000 after purchasing an additional 155,172 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in ACADIA Pharmaceuticals by 2.9% during the third quarter. TIAA CREF Investment Management LLC now owns 565,674 shares of the biopharmaceutical company’s stock valued at $11,743,000 after purchasing an additional 15,850 shares in the last quarter. Teachers Advisors LLC raised its position in ACADIA Pharmaceuticals by 3.0% during the third quarter. Teachers Advisors LLC now owns 250,406 shares of the biopharmaceutical company’s stock valued at $5,198,000 after purchasing an additional 7,358 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in ACADIA Pharmaceuticals during the third quarter valued at about $2,345,000. Finally, MetLife Investment Advisors LLC raised its position in ACADIA Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 71,090 shares of the biopharmaceutical company’s stock valued at $1,476,000 after purchasing an additional 25,271 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.
ACADIA Pharmaceuticals stock opened at $18.21 on Friday. ACADIA Pharmaceuticals has a one year low of $12.77 and a one year high of $32.99. The firm has a market capitalization of $2.35 billion, a PE ratio of -7.72 and a beta of 3.36.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Recommended Story: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.